Abstract:Objective To explore the clinicopathological features,diagnosis,differential diagnosis and treatment of congenital hemangioma (CH).Methods The clinical data,pathological characteristics and treatment of 32 CH cases were analyzed retrospectively.Results There were 20 boys and 12 girls with a boy-to-girl ratio of 1.6∶1 and a median age of 43 months.All were unifocal lesions at head & neck region (n =8),trunk (n =12),upper extremities (n =5) and lower extremities (n =7).One lesion was detected by prenatal ultrasonography and the remainder was present at birth.Twenty-five lesions gradually expanded in size,3 lesions had slight regression and 4 cases showed no obvious changes.One lesion felt warm on palpation,one with sinus at the center of mass while the remainder had no local pain,swelling or ulceration.All lesions had normal preoperative results of blood routine and blood coagulation function.One child received a preoperative injection of sclerosant.However,mass had no regression.All cases underwent complete resection.One child of excessive intraoperative hemorrhage received blood transfusion postoperatively.The clinical types were rapidly involuting congenital hemangioma (RICH,n =3) and noninvoluting congenital hemangioma (NICH,n =29).NICH:Tumor was dominated by lobules of capillaries,separated by dense fibrous tissues containing lymphatic vessels and small arteriovenous structures.Small intralobular vessels were lined by endothelial cells with hobnailed nuclei.The center of lobule was occupied by stelliform vessels.RICH:Tumor was dominated by lobules of capillaries,similar to those seen in NICH,most intralobular vessels were atretic and the remainder diminished.Endothelial cells became flattened.Focal hemorrhagic necrosis,hemosiderosis and calcification were observed.Immunohistochemistry showed that all cases were negative for Glut1,positive for CD34(32/32),CD31 (32/32) and WT1 (32/32) and D2-40 was partially positive.Twenty-five cases were followed up for 3-25 months.Slight linear scar was present.Recurrence was not found.Conclusions CH is a benign vascular tumor whose diagnosis (RICH or NICH) depends upon clinical manifestations and pathological morphology.Clinically and pathologically,it needs to be differentiated from vascular malformation,infantile hemangiomas,kaposiform hemangioendothelioma and pyogenic granuloma.

KLF2 Orchestrates Pathological Progression of Infantile Hemangioma through Hemangioma Stem Cell Fate Decisions

Cell Fate Regulation During the Development of Infantile Hemangioma

Biology of Infantile Hemangioma

Signaling pathways in the development of infantile hemangioma

CD146+ mural cells from infantile hemangioma display proangiogenic ability and adipogenesis potential in vitro and in xenograft models

Three-Dimensional Microtumor Formation of Infantile Hemangioma-Derived Endothelial Cells for Mechanistic Exploration and Drug Screening

Infantile hemangioma: the common and enigmatic vascular tumor

Infantile haemangioma: Part I. Pathophysiology, epidemiology, clinical features, life cycle and associated structural abnormalities

Targeting ESM1 via SOX4 promotes the progression of infantile hemangioma through the PI3K/AKT signaling pathway

Insights into the mechanisms of angiogenesis in infantile hemangioma

Infantile hemangioma models: is the needle in a haystack?

Divergent roles for KLF4 and TFCP2L1 in Naive Ground State Pluripotency and Human Primordial Germ Cell Development

IL13RA2 promotes progression of infantile haemangioma by activating glycolysis and the Wnt/β-catenin signaling pathway

Characterization of epigenetic and transcriptional landscape in infantile hemangiomas with ATAC-seq and RNA-seq

CENPF May Act as a Novel Marker and Highlight the Influence of Pericyte in Infantile Hemangioma

ALKBH5 facilitates the progression of infantile hemangioma by increasing FOXF1 expression in a m6A-YTHDF2 dependent manner to activate HK-2 signaling

Identification of Potential Therapeutics for Infantile Hemangioma via in silico Investigation and in vitro Validation

Progress In The Treatment Of Infantile Hemangioma

Management of congenital hemangioma: clinicopathological analysis of 32 cases

ALKBH5 promotes the progression of infantile hemangioma through regulating the NEAT1/miR-378b/FOSL1 axis

Mast cell in infantile hemangioma